PND40 BUDGET IMPACT ANALYSIS OF GALCANEZUMAB-GNLM FOR THE PREVENTIVE TREATMENT OF PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE IN THE UNITED STATES
May 1, 2019, 00:00 AM
10.1016/j.jval.2019.04.1313
https://www.valueinhealthjournal.com/article/S1098-3015(19)31505-0/fulltext
Section Title :
Section Order :
10814
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)31505-0&doi=10.1016/j.jval.2019.04.1313